


3. (amended) Use according to claim 1 wherein the compound having NMDA receptor antagonist activity is a compound of formula(I):



where:

R^1 and R^2 are independently phenyl or 4-fluorophenyl;

R^3 is hydrogen, C_{1-6} alkyl or methoxycarbonyl;

R^4 is hydrogen or methyl;

and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof.

A2

9. (amended) A method of treating or preventing irritable bowel syndrome which comprises administering to a patient in the need thereof a compound having NMDA receptor antagonist activity or a pharmaceutically acceptable salt thereof.

10. (amended) A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound having NMDA receptor antagonist activity and a pharmaceutically acceptable carrier.

11. (amended) [Pharmaceutical] The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor